A phase I/IIa study of BMS986148 a Mesothelin directed antibody drug conjugate in subjects with select advanced solid tumors
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Bristol-Myers Squibb Company
Start Date
May 1, 2015
End Date
April 30, 2023
Administered By
Duke Cancer Institute
Awarded By
Bristol-Myers Squibb Company
Start Date
May 1, 2015
End Date
April 30, 2023